

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/163535 A1

(51) International Patent Classification:

C07K 14/605 (2006.01) A61K 47/54 (2017.01)
A61K 38/00 (2006.01) A61P 3/04 (2006.01)
A61K 38/26 (2006.01) A61P 3/10 (2006.01)

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/013645

(22) International Filing Date:

31 January 2024 (31.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/482,404 31 January 2023 (31.01.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **ABRAHAM, Milata Mary**; c/o ELI LILLY
AND COMPANY, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **BROWN, Robert Andrew**; c/o ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indi-
ana 46206-6288 (US). **COSKUN, Tamer**; c/o ELI LIL-
LY AND COMPANY, P.O. Box 6288, Indianapolis, Indi-
ana 46206-6288 (US). **FLORA, David Benjamin**; c/o ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis,
Indiana 46206-6288 (US). **KLEINDL, Paul Joseph**; c/o
ELI LILLY AND COMPANY, P.O. Box 6288, Indianapo-
lis, Indiana 46206-6288 (US). **QU, Fucheng**; c/o ELI LIL-
LY AND COMPANY, P.O. Box 6288, Indianapolis, Indi-
ana 46206-6288 (US). **QU, Hongchang**; c/o ELI LILLY
AND COMPANY, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **WALLIS, James Lincoln**; c/o ELI LIL-
LY AND COMPANY, P.O. Box 6288, Indianapolis, Indi-
ana 46206-6288 (US).

(74) Agent: **LORD, Matthew T.** et al.; c/o Eli Lilly and Compa-
ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF

(57) Abstract: Polypeptides are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The polypeptides have structural features resulting in activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases and/or conditions such as obesity, chronic weight management, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, Chronic Kidney Disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS).



WO 2024/163535 A1